Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Vaccines

Free Subscription Articles published in Nat Med Retrieve available abstracts of 105 articles: HTML format

Single Articles

July 2021
1. MACHINGAIDZE S, Wiysonge CS
   Understanding COVID-19 vaccine hesitancy.
   Nat Med. 2021 Jul 16. pii: 10.1038/s41591-021-01459.
   PubMed    
   
   
   
2. SOLIS ARCE JS, Warren SS, Meriggi NF, Scacco A, et al
   COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries.
   Nat Med. 2021 Jul 16. pii: 10.1038/s41591-021-01454.
   PubMed     Abstract available
   
   
   
3. O'LEARY K
   Another COVID-19 vaccine to boost rollout.
   Nat Med. 2021 Jul 15. pii: 10.1038/d41591-021-00045.
   PubMed    
   
   
   
4. BARROS-MARTINS J, Hammerschmidt SI, Cossmann A, Odak I, et al
   Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.
   Nat Med. 2021 Jul 14. pii: 10.1038/s41591-021-01449.
   PubMed     Abstract available
   
   
   
5. LOUBET P, Wittkop L, Tartour E, Parfait B, et al
   A French cohort for assessing COVID-19 vaccine responses in specific populations.
   Nat Med. 2021 Jul 12. pii: 10.1038/s41591-021-01435.
   PubMed    
   
   
   
6. CHEMAITELLY H, Yassine HM, Benslimane FM, Al Khatib HA, et al
   mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.
   Nat Med. 2021 Jul 9. pii: 10.1038/s41591-021-01446.
   PubMed     Abstract available
   
   
   
7. KRAMMER F
   A correlate of protection for SARS-CoV-2 vaccines is urgently needed.
   Nat Med. 2021 Jul 8. pii: 10.1038/s41591-021-01432.
   PubMed    
   
   
   
8. COWLING BJ, Lim WW, Cobey S
   Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality.
   Nat Med. 2021 Jul 5. pii: 10.1038/s41591-021-01440.
   PubMed    
   
   
   June 2021
9. O'LEARY K
   Building a pandemic-proof vaccine.
   Nat Med. 2021 Jun 28. pii: 10.1038/d41591-021-00042.
   PubMed    
   
   
   
10. SALJE H, Alera MT, Chua MN, Hunsawong T, et al
    Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection.
    Nat Med. 2021 Jun 24. pii: 10.1038/s41591-021-01392.
    PubMed     Abstract available
    
    
    
11. KUSTIN T, Harel N, Finkel U, Perchik S, et al
    Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals.
    Nat Med. 2021 Jun 14. pii: 10.1038/s41591-021-01413.
    PubMed     Abstract available
    
    
    
12. MILMAN O, Yelin I, Aharony N, Katz R, et al
    Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals.
    Nat Med. 2021 Jun 10. pii: 10.1038/s41591-021-01407.
    PubMed     Abstract available
    
    
    
13. PRITCHARD E, Matthews PC, Stoesser N, Eyre DW, et al
    Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom.
    Nat Med. 2021 Jun 9. pii: 10.1038/s41591-021-01410.
    PubMed     Abstract available
    
    
    
14. PISHKO AM, Bussel JB, Cines DB
    COVID-19 vaccination and immune thrombocytopenia.
    Nat Med. 2021 Jun 9. pii: 10.1038/s41591-021-01419.
    PubMed    
    
    
    
15. SIMPSON CR, Shi T, Vasileiou E, Katikireddi SV, et al
    First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.
    Nat Med. 2021 Jun 9. pii: 10.1038/s41591-021-01408.
    PubMed     Abstract available
    
    
    
16. ROSSMAN H, Shilo S, Meir T, Gorfine M, et al
    COVID-19 dynamics after a national immunization program in Israel.
    Nat Med. 2021;27:1055-1061.
    PubMed     Abstract available
    
    
    
17. 
    To curb COVID-19, global health must go local.
    Nat Med. 2021;27:929.
    PubMed    
    
    
    May 2021
18. MAY M
    After COVID-19 successes, researchers push to develop mRNA vaccines for other diseases.
    Nat Med. 2021 May 31. pii: 10.1038/s41591-021-01393.
    PubMed    
    
    
    
19. AU L, Fendler A, Shepherd STC, Rzeniewicz K, et al
    Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
    Nat Med. 2021 May 26. pii: 10.1038/s41591-021-01387.
    PubMed     Abstract available
    
    
    
20. EWER KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, et al
    Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
    Nat Med. 2021 May 21. pii: 10.1038/s41591-021-01363.
    PubMed    
    
    
    
21. SCHMIDT H, Weintraub R, Williams MA, Miller K, et al
    Equitable allocation of COVID-19 vaccines in the United States.
    Nat Med. 2021 May 18. pii: 10.1038/s41591-021-01379.
    PubMed     Abstract available
    
    
    
22. WARD BJ, Gobeil P, Seguin A, Atkins J, et al
    Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
    Nat Med. 2021 May 18. pii: 10.1038/s41591-021-01370.
    PubMed     Abstract available
    
    
    
23. BARRETT JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, et al
    Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
    Nat Med. 2021 May 6. pii: 10.1038/s41591-021-01372.
    PubMed    
    
    
    
24. SINGH JA, Kochhar S, Wolff J
    Author Correction: Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group.
    Nat Med. 2021 May 4. pii: 10.1038/s41591-021-01360.
    PubMed    
    
    
    
25. ANDREANO E, Rappuoli R
    SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies.
    Nat Med. 2021;27:759-761.
    PubMed    
    
    
    
26. OTU A, Agogo E, Ebenso B
    Africa needs more genome sequencing to tackle new variants of SARS-CoV-2.
    Nat Med. 2021;27:744-745.
    PubMed    
    
    
    April 2021
27. 
    COVID-19 vaccine and blood clotting.
    Nat Med. 2021 Apr 29. pii: 10.1038/d41591-021-00025.
    PubMed    
    
    
    
28. DAL-RE R, Orenstein W, Caplan AL
    Being fair to participants in placebo-controlled COVID-19 vaccine trials.
    Nat Med. 2021 Apr 26. pii: 10.1038/s41591-021-01338.
    PubMed    
    
    
    
29. LI J, Hui A, Zhang X, Yang Y, et al
    Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
    Nat Med. 2021 Apr 22. pii: 10.1038/s41591-021-01330.
    PubMed     Abstract available
    
    
    
30. ZARD M, Lau LS, Bowser DM, Fouad FM, et al
    Leave no one behind: ensuring access to COVID-19 vaccines for refugee and displaced populations.
    Nat Med. 2021 Apr 19. pii: 10.1038/s41591-021-01328.
    PubMed    
    
    
    
31. GIORDANO G, Colaneri M, Di Filippo A, Blanchini F, et al
    Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy.
    Nat Med. 2021 Apr 16. pii: 10.1038/s41591-021-01334.
    PubMed     Abstract available
    
    
    
32. BAUSCH DG
    The need for a new strategy for Ebola vaccination.
    Nat Med. 2021 Apr 5. pii: 10.1038/s41591-021-01313.
    PubMed    
    
    
    
33. EBINGER JE, Fert-Bober J, Printsev I, Wu M, et al
    Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
    Nat Med. 2021 Apr 1. pii: 10.1038/s41591-021-01325.
    PubMed     Abstract available
    
    
    
34. EXCLER JL, Saville M, Berkley S, Kim JH, et al
    Vaccine development for emerging infectious diseases.
    Nat Med. 2021;27:591-600.
    PubMed     Abstract available
    
    
    
35. CHEN RE, Zhang X, Case JB, Winkler ES, et al
    Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.
    Nat Med. 2021;27:717-726.
    PubMed     Abstract available
    
    
    
36. WIBMER CK, Ayres F, Hermanus T, Madzivhandila M, et al
    SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
    Nat Med. 2021;27:622-625.
    PubMed     Abstract available
    
    
    
37. BURIONI R, Topol EJ
    Assessing the human immune response to SARS-CoV-2 variants.
    Nat Med. 2021;27:571-572.
    PubMed    
    
    
    
38. KINGANDA-LUSAMAKI E, Black A, Mukadi DB, Hadfield J, et al
    Integration of genomic sequencing into the response to the Ebola virus outbreak in Nord Kivu, Democratic Republic of the Congo.
    Nat Med. 2021;27:710-716.
    PubMed     Abstract available
    
    
    March 2021
39. CLARKE PM, Roope LSJ, Loewen PJ, Bonnefon JF, et al
    Public opinion on global rollout of COVID-19 vaccines.
    Nat Med. 2021 Mar 30. pii: 10.1038/s41591-021-01322.
    PubMed    
    
    
    
40. LEVINE-TIEFENBRUN M, Yelin I, Katz R, Herzel E, et al
    Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine.
    Nat Med. 2021 Mar 29. pii: 10.1038/s41591-021-01316.
    PubMed     Abstract available
    
    
    
41. PLANAS D, Bruel T, Grzelak L, Guivel-Benhassine F, et al
    Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.
    Nat Med. 2021 Mar 26. pii: 10.1038/s41591-021-01318.
    PubMed     Abstract available
    
    
    
42. SARGENT J
    Vaccines reduce childhood mortality.
    Nat Med. 2021 Mar 18. pii: 10.1038/d41591-021-00014.
    PubMed    
    
    
    
43. SINGH JA, Kochhar S, Wolff J
    Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group.
    Nat Med. 2021 Mar 16. pii: 10.1038/s41591-021-01299.
    PubMed    
    
    
    
44. EKSTROM AM, Berggren C, Tomson G, Gostin LO, et al
    The battle for COVID-19 vaccines highlights the need for a new global governance mechanism.
    Nat Med. 2021 Mar 11. pii: 10.1038/s41591-021-01288.
    PubMed    
    
    
    
45. MARHOLD K, Fell J
    Electronic vaccination certificates: avoiding a repeat of the contact-tracing 'format wars'.
    Nat Med. 2021 Mar 4. pii: 10.1038/s41591-021-01286.
    PubMed    
    
    
    
46. DURRHEIM DN, Andrus JK, Tabassum S, Bashour H, et al
    A dangerous measles future looms beyond the COVID-19 pandemic.
    Nat Med. 2021;27:360-361.
    PubMed    
    
    
    
47. AHMED I
    Dismantling the anti-vaxx industry.
    Nat Med. 2021;27:366.
    PubMed    
    
    
    February 2021
48. VAN DER VELDT AAM, Oosting SF, Dingemans AC, Fehrmann RSN, et al
    COVID-19 vaccination: the VOICE for patients with cancer.
    Nat Med. 2021 Feb 15. pii: 10.1038/s41591-021-01240.
    PubMed    
    
    
    
49. XIE X, Liu Y, Liu J, Zhang X, et al
    Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.
    Nat Med. 2021 Feb 8. pii: 10.1038/s41591-021-01270.
    PubMed     Abstract available
    
    
    
50. 
    COVID-19 vaccines: acting on the evidence.
    Nat Med. 2021 Feb 4. pii: 10.1038/s41591-021-01261.
    PubMed    
    
    
    
51. STOWER H
    A functioning vaccine in mouse models of multiple sclerosis.
    Nat Med. 2021 Feb 1. pii: 10.1038/d41591-021-00006.
    PubMed    
    
    
    January 2021
52. HU Z, Leet DE, Allesoe RL, Oliveira G, et al
    Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.
    Nat Med. 2021 Jan 21. pii: 10.1038/s41591-020-01206.
    PubMed     Abstract available
    
    
    
53. KIM JH, Marks F, Clemens JD
    Looking beyond COVID-19 vaccine phase 3 trials.
    Nat Med. 2021 Jan 19. pii: 10.1038/s41591-021-01230.
    PubMed     Abstract available
    
    
    
54. LAZARUS JV, Ratzan SC, Palayew A, Gostin LO, et al
    Author Correction: A global survey of potential acceptance of a COVID-19 vaccine.
    Nat Med. 2021 Jan 11. pii: 10.1038/s41591-020-01226.
    PubMed    
    
    
    
55. KAMPMANN B
    Women and children last? Shaking up exclusion criteria for vaccine trials.
    Nat Med. 2021;27:8.
    PubMed    
    
    
    
56. WAGAR LE, Salahudeen A, Constantz CM, Wendel BS, et al
    Modeling human adaptive immune responses with tonsil organoids.
    Nat Med. 2021;27:125-135.
    PubMed     Abstract available
    
    
    
57. BURTON DR, Topol EJ
    Toward superhuman SARS-CoV-2 immunity?
    Nat Med. 2021;27:5-6.
    PubMed    
    
    
    December 2020
58. EWER KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, et al
    T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
    Nat Med. 2020 Dec 17. pii: 10.1038/s41591-020-01194.
    PubMed     Abstract available
    
    
    
59. BARRETT JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, et al
    Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
    Nat Med. 2020 Dec 17. pii: 10.1038/s41591-020-01179.
    PubMed     Abstract available
    
    
    
60. NACHBAGAUER R, Feser J, Naficy A, Bernstein DI, et al
    A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.
    Nat Med. 2020 Dec 7. pii: 10.1038/s41591-020-1118.
    PubMed     Abstract available
    
    
    
61. CARVALHO T
    Vaccines in the fast lane.
    Nat Med. 2020;26:1807.
    PubMed    
    
    
    November 2020
62. GALLAGHER ME, Sieben AJ, Nelson KN, Kraay ANM, et al
    Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates.
    Nat Med. 2020 Nov 23. pii: 10.1038/s41591-020-01172.
    PubMed    
    
    
    October 2020
63. LAZARUS JV, Ratzan SC, Palayew A, Gostin LO, et al
    A global survey of potential acceptance of a COVID-19 vaccine.
    Nat Med. 2020 Oct 20. pii: 10.1038/s41591-020-1124.
    PubMed     Abstract available
    
    
    
64. 
    Scientists, keep an open line of communication with the public.
    Nat Med. 2020;26:1495.
    PubMed    
    
    
    September 2020
65. STOWER H
    Developing COVID-19 vaccines.
    Nat Med. 2020 Sep 10. pii: 10.1038/d41591-020-00029.
    PubMed    
    
    
    
66. TOSTANOSKI LH, Wegmann F, Martinot AJ, Loos C, et al
    Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters.
    Nat Med. 2020 Sep 3. pii: 10.1038/s41591-020-1070.
    PubMed     Abstract available
    
    
    August 2020
67. EDWARDS KM
    Vaccines targeting SARS-CoV-2 tested in humans.
    Nat Med. 2020 Aug 24. pii: 10.1038/s41591-020-1048.
    PubMed    
    
    
    
68. STOWER H
    Seeds of hope in COVID-19 vaccine preliminary data.
    Nat Med. 2020;26:1170.
    PubMed    
    
    
    
69. PARK JK, Xiao Y, Ramuta MD, Rosas LA, et al
    Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model.
    Nat Med. 2020;26:1240-1246.
    PubMed     Abstract available
    
    
    July 2020
70. ARNOLD C
    How computational immunology changed the face of COVID-19 vaccine development.
    Nat Med. 2020 Jul 15. pii: 10.1038/d41591-020-00027.
    PubMed    
    
    
    June 2020
71. STOWER H
    Vaccination combats antimicrobial resistance.
    Nat Med. 2020 Jun 11. pii: 10.1038/s41591-020-0957.
    PubMed    
    
    
    
72. 'T HOEN E
    Protect against market exclusivity in the fight against COVID-19.
    Nat Med. 2020;26:813.
    PubMed    
    
    
    May 2020
73. ARUNACHALAM PS, Charles TP, Joag V, Bollimpelli VS, et al
    T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers.
    Nat Med. 2020 May 11. pii: 10.1038/s41591-020-0858.
    PubMed     Abstract available
    
    
    April 2020
74. MOTHE B, Brander C
    Small steps forward for HIV vaccine development.
    Nat Med. 2020 Apr 2. pii: 10.1038/s41591-020-0837.
    PubMed    
    
    
    March 2020
75. COLBY DJ, Sarnecki M, Barouch DH, Tipsuk S, et al
    Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption.
    Nat Med. 2020 Mar 23. pii: 10.1038/s41591-020-0774.
    PubMed     Abstract available
    
    
    
76. TADROS AR, Romanyuk A, Miller IC, Santiago A, et al
    STAR particles for enhanced topical drug and vaccine delivery.
    Nat Med. 2020;26:341-347.
    PubMed     Abstract available
    
    
    February 2020
77. KOTLIAROV Y, Sparks R, Martins AJ, Mule MP, et al
    Broad immune activation underlies shared set point signatures for vaccine responsiveness in healthy individuals and disease activity in patients with lupus.
    Nat Med. 2020 Feb 24. pii: 10.1038/s41591-020-0769.
    PubMed     Abstract available
    
    
    
78. LANGENBERG MCC, Hoogerwerf MA, Koopman JPR, Janse JJ, et al
    A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics.
    Nat Med. 2020 Feb 17. pii: 10.1038/s41591-020-0759.
    PubMed     Abstract available
    
    
    
79. DUSSUPT V, Sankhala RS, Gromowski GD, Donofrio G, et al
    Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.
    Nat Med. 2020 Feb 3. pii: 10.1038/s41591-019-0746.
    PubMed     Abstract available
    
    
    
80. DORE GJ, Martinello M, Alavi M, Grebely J, et al
    Global elimination of hepatitis C virus by 2030: why not?
    Nat Med. 2020;26:157-160.
    PubMed    
    
    
    January 2020
81. STOWER H
    A conjugate vaccine for typhoid.
    Nat Med. 2020;26:21.
    PubMed    
    
    
    October 2019
82. EHRHARDT SA, Zehner M, Krahling V, Cohen-Dvashi H, et al
    Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.
    Nat Med. 2019 Oct 7. pii: 10.1038/s41591-019-0602.
    PubMed     Abstract available
    
    
    
83. STOWER H
    Supporting HPV vaccination.
    Nat Med. 2019 Oct 7. pii: 10.1038/s41591-019-0618.
    PubMed    
    
    
    
84. SAPHIRE EO
    A glimpse into immune responses evolving against Ebola virus.
    Nat Med. 2019;25:1470-1471.
    PubMed    
    
    
    August 2019
85. CHAN KR, Gan ES, Chan CYY, Liang C, et al
    Metabolic perturbations and cellular stress underpin susceptibility to symptomatic live-attenuated yellow fever infection.
    Nat Med. 2019;25:1218-1224.
    PubMed     Abstract available
    
    
    
86. PEEPLES L
    Rethinking herd immunity.
    Nat Med. 2019;25:1178-1180.
    PubMed    
    
    
    July 2019
87. 
    Time to vaccinate against hesitancy.
    Nat Med. 2019 Jul 3. pii: 10.1038/s41591-019-0524.
    PubMed    
    
    
    May 2019
88. 
    HIV vaccines go to trial.
    Nat Med. 2019;25:703.
    PubMed    
    
    
    April 2019
89. HAMMERICH L, Marron TU, Upadhyay R, Svensson-Arvelund J, et al
    Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination.
    Nat Med. 2019 Apr 8. pii: 10.1038/s41591-019-0410.
    PubMed     Abstract available
    
    
    January 2019
90. YAMAYOSHI S, Kawaoka Y
    Current and future influenza vaccines.
    Nat Med. 2019 Jan 28. pii: 10.1038/s41591-018-0340.
    PubMed     Abstract available
    
    
    
91. DIJKMAN K, Sombroek CC, Vervenne RAW, Hofman SO, et al
    Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques.
    Nat Med. 2019 Jan 21. pii: 10.1038/s41591-018-0319.
    PubMed     Abstract available
    
    
    November 2018
92. FARRELL A
    A vaccine for tuberculosis.
    Nat Med. 2018;24:1637.
    PubMed    
    
    
    September 2018
93. ACKERMAN ME, Das J, Pittala S, Broge T, et al
    Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV.
    Nat Med. 2018 Sep 3. pii: 10.1038/s41591-018-0161.
    PubMed     Abstract available
    
    
    August 2018
94. OKOYE AA, Hansen SG, Vaidya M, Fukazawa Y, et al
    Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound.
    Nat Med. 2018 Aug 6. pii: 10.1038/s41591-018-0130.
    PubMed     Abstract available
    
    
    June 2018
95. XU K, Acharya P, Kong R, Cheng C, et al
    Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.
    Nat Med. 2018;24:857-867.
    PubMed     Abstract available
    
    
    May 2018
96. VACCARI M, Fourati S, Gordon SN, Brown DR, et al
    HIV vaccine candidate activation of hypoxia and the inflammasome in CD14(+) monocytes is associated with a decreased risk of SIVmac251 acquisition.
    Nat Med. 2018 May 21. pii: 10.1038/s41591-018-0025.
    PubMed     Abstract available
    
    
    April 2018
97. 
    A checkup for the flu vaccine.
    Nat Med. 2018;24:375.
    PubMed    
    
    
    
98. DRAPER SJ, Higgins MK
    A new site of attack for a malaria vaccine.
    Nat Med. 2018;24:382-383.
    PubMed    
    
    
    March 2018
99. CHAKRADHAR S
    Going live: How microRNAs might bring living vaccines back into the fold.
    Nat Med. 2018;24:248-250.
    PubMed    
    
    
    February 2018
100. JAYARAMAN K
     A shot at contraception: In India, a nonagenarian renews testing of a birth control vaccine.
     Nat Med. 2018;24:118-120.
     PubMed    
     
     
     
101. CARPENTER SM, Behar SM
     A new vaccine for tuberculosis in rhesus macaques.
     Nat Med. 2018;24:124-126.
     PubMed    
     
     
     January 2018
102. HANSEN SG, Zak DE, Xu G, Ford JC, et al
     Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine.
     Nat Med. 2018 Jan 15. pii: nm.4473. doi: 10.1038/nm.4473.
     PubMed     Abstract available
     
     
     
103. JANSEN KU, Knirsch C, Anderson AS
     The role of vaccines in preventing bacterial antimicrobial resistance.
     Nat Med. 2018;24:10-19.
     PubMed     Abstract available
     
     
     November 2017
104. ARNOLD C
     Stalking new vaccines: Methods that target the stems of viral proteins could put universal vaccines within reach.
     Nat Med. 2017;23:1248-1250.
     PubMed    
     
     
     July 2016
105. MODJARRAD K, Moorthy VS, Ben Embarek P, Van Kerkhove M, et al
     A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation.
     Nat Med. 2016;22:701-5.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: